CY1110972T1 - Ανοσοκαταστολη με σαπερονινη 10 - Google Patents

Ανοσοκαταστολη με σαπερονινη 10

Info

Publication number
CY1110972T1
CY1110972T1 CY20101101115T CY101101115T CY1110972T1 CY 1110972 T1 CY1110972 T1 CY 1110972T1 CY 20101101115 T CY20101101115 T CY 20101101115T CY 101101115 T CY101101115 T CY 101101115T CY 1110972 T1 CY1110972 T1 CY 1110972T1
Authority
CY
Cyprus
Prior art keywords
donor
recipient animal
saperonin
immune
cpn10
Prior art date
Application number
CY20101101115T
Other languages
English (en)
Inventor
Geoffrey R Hill
Tatjana Banovic
Halle Morton
Alice Christina Cavanagh
Original Assignee
Cbio Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbio Limited filed Critical Cbio Limited
Publication of CY1110972T1 publication Critical patent/CY1110972T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση κατευθύνεται προς την χρήση της cpn10 στην μεταμόσχευση και ιδιαίτερα στην αγωγή και/ή πρόληψη της νόσου του μοσχεύματος κατά του ξενιστή. Η εφεύρεση παρέχει μία μέθοδο χορήγησης cpn10 σε έναν δότη και/ή λήπτη ζώο ή κύτταρα, ιστούς ή όργανα που προέρχονται από τον δότη, όμως σε μια ιδιαιτέρως ωφέλιμη μορφή αγωγής και του δότη και του λήπτη ζώου. Η μέθοδος μπορεί επίσης να περιλαμβάνει την χορήγηση σε δότη και/ή λήπτη ζώο τουλάχιστον ενός άλλου ανοσοκατασταλτικού παράγοντα για να αποτραπεί ή να αμβλυνθεί η νόσος του μοσχεύματος κατά του ξενιστή.
CY20101101115T 2002-11-06 2010-12-03 Ανοσοκαταστολη με σαπερονινη 10 CY1110972T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002952492A AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression
EP03769073A EP1569679B1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression

Publications (1)

Publication Number Publication Date
CY1110972T1 true CY1110972T1 (el) 2015-06-11

Family

ID=28795882

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101115T CY1110972T1 (el) 2002-11-06 2010-12-03 Ανοσοκαταστολη με σαπερονινη 10

Country Status (16)

Country Link
US (3) US7618935B2 (el)
EP (3) EP2255824B1 (el)
JP (2) JP4716731B2 (el)
KR (1) KR101088740B1 (el)
CN (1) CN100525832C (el)
AT (1) ATE489963T1 (el)
AU (1) AU2002952492A0 (el)
CA (1) CA2505141C (el)
CY (1) CY1110972T1 (el)
DE (1) DE60335202D1 (el)
DK (1) DK1569679T3 (el)
ES (1) ES2351993T3 (el)
NZ (1) NZ540433A (el)
PT (1) PT1569679E (el)
SI (1) SI1569679T1 (el)
WO (1) WO2004041300A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005204979B2 (en) * 2004-01-16 2010-10-21 Cbio Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
KR20060114011A (ko) * 2004-01-16 2006-11-03 씨바이오 리미티드 Ｔｏｌｌ-유사 수용체 유도성 사이토킨 및 케모킨 분비의샤페로닌 10 조절
US8036710B2 (en) * 2004-05-07 2011-10-11 Qualcomm, Incorporated Power-efficient multi-antenna wireless device
JP2009500430A (ja) * 2005-07-11 2009-01-08 シーバイオ リミテッド シャペロニン１０により誘導される免疫調整方法
AU2006269824B2 (en) * 2005-07-11 2012-04-19 Cbio Limited Chaperonin 10-induced immunomodulation
US7977458B2 (en) 2005-08-31 2011-07-12 Cbio Limited Modified chaperonin 10
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
US20090087410A1 (en) * 2005-10-20 2009-04-02 Cbio Limited Treatment of hypersensitivity
WO2007098557A1 (en) 2006-03-02 2007-09-07 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
MX2010011169A (es) * 2008-04-11 2011-03-01 Cbio Ltd Cpn10 modificada y señalizacion de prr.
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
US9688741B2 (en) 2012-10-23 2017-06-27 Elastagen Pty Ltd Elastic hydrogel
US10842913B2 (en) 2012-12-10 2020-11-24 Allergan Pharmaceuticals International Limited Scalable three-dimensional elastic construct manufacturing
BR112016003082A8 (pt) 2013-08-13 2020-01-28 Elastagen Pty Ltd uso da tropoelastina na produção de um medicamento para cicatrização de uma ferida ou para melhora da reepitelização de uma ferida

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176948C (en) * 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
JP3987104B2 (ja) 1993-11-30 2007-10-03 ザ・ユニバーシティ・オブ・クイーンズランド シャペロニン１０のアンタゴニスト
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
AU712606B2 (en) * 1995-08-09 1999-11-11 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
AU7361900A (en) 1999-09-10 2001-04-10 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method

Also Published As

Publication number Publication date
WO2004041300A1 (en) 2004-05-21
JP2006508099A (ja) 2006-03-09
ES2351993T3 (es) 2011-02-14
CN100525832C (zh) 2009-08-12
JP2011088920A (ja) 2011-05-06
PT1569679E (pt) 2010-12-14
NZ540433A (en) 2008-03-28
CA2505141C (en) 2012-07-17
EP2255824B1 (en) 2014-07-23
EP1569679B1 (en) 2010-12-01
CA2505141A1 (en) 2004-05-21
US20100099605A1 (en) 2010-04-22
US8067361B2 (en) 2011-11-29
EP1569679A1 (en) 2005-09-07
EP1569679A4 (en) 2008-02-27
ATE489963T1 (de) 2010-12-15
DE60335202D1 (en) 2011-01-13
US7618935B2 (en) 2009-11-17
DK1569679T3 (da) 2011-01-10
EP2818179A1 (en) 2014-12-31
JP4716731B2 (ja) 2011-07-06
AU2002952492A0 (en) 2002-11-21
US20120082690A1 (en) 2012-04-05
SI1569679T1 (sl) 2011-01-31
KR20050086428A (ko) 2005-08-30
KR101088740B1 (ko) 2011-12-01
US20060198834A1 (en) 2006-09-07
EP2255824A1 (en) 2010-12-01
CN1735428A (zh) 2006-02-15

Similar Documents

Publication Publication Date Title
CY1110972T1 (el) Ανοσοκαταστολη με σαπερονινη 10
BR0203650A (pt) Estentor de auto-articulação
DK1487431T3 (da) Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
ATE395418T1 (de) Alpha(1,3)galactosyltransferase-negatives schwein
ATE400577T1 (de) Anellierte dihydropyrane
EA200300738A1 (ru) Защита, восстановление и усиление эритропоэтинреактивных клеток, тканей и органов
YU97402A (sh) Koštana (transkutalna) proteza
DE60330468D1 (de) Schweine ohne jegliche expression funktioneller alpha-1,3-galactosyltransferase
NO20052505L (no) Ny bruk av dextran-sulfat
DE69833937D1 (de) Verwendung von zinkhyaluronat gegen magengeschwür
HK1060855A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment ofdelayed graft function
RS51420B (en) HYPERSTRUCTURE AMYLOPECTIN FOR USE IN THE PROCEDURES OF SURGICAL OR THERAPEUTIC TREATMENT OF mammals OR IN THE PROCEDURES OF DIAGNOSIS, AND PARTICULARLY FOR USE AS A PLASMA VOLUME EXPANDER
EP0929217A4 (en) SORDARIN DERIVATIVES
TR200002847T2 (tr) Biçim VI 5, 6-dikloro-2-(izopropilamino) -1-(beta-L-ribofüranosil) -1H-benzimidazol.
FR2811229B1 (fr) Utilisation d'un polysaccharide excrete par l'espece vibrio diabolicus en cicatrisation osseuse
BG104259A (en) Derivatives of 4-cyano-4-deformylsordaricin
BG104258A (en) 4-cyano-4-deformylsordarin derivatives
MD980129A (en) Antiherpetic remedy
NO20016326L (no) Anvendelse av proteinet UK 114 for å hindre avstötning av organtransplantatet
史梦 Even
of Man An act (Chapter No. 3) to prohibit commercial dealings in human organs intended for transplanting; to prohibit the transplanting of such organs between persons who are not genetically related; and for connected purposes. Dated 16 March 1993.(The Human Organ Transplants Act 1993)
Begley et al. World's First Mechanical Heart Implanted
ATE253378T1 (de) Xenogene transplantation